A detailed history of Marshall Wace, LLP transactions in Eton Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 36,182 shares of ETON stock, worth $568,057. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,182
Previous 20,637 75.33%
Holding current value
$568,057
Previous $123,000 286.18%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$5.9 - $13.15 $91,715 - $204,416
15,545 Added 75.33%
36,182 $475,000
Q3 2024

Nov 14, 2024

BUY
$3.28 - $6.0 $67,689 - $123,822
20,637 New
20,637 $123,000
Q1 2022

May 16, 2022

SELL
$3.43 - $4.69 $315,875 - $431,911
-92,092 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$3.66 - $6.59 $26,278 - $47,316
7,180 Added 8.46%
92,092 $395,000
Q2 2021

Aug 13, 2021

BUY
$5.71 - $8.85 $484,847 - $751,471
84,912 New
84,912 $523,000

Others Institutions Holding ETON

About Eton Pharmaceuticals, Inc.


  • Ticker ETON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,297,000
  • Market Cap $397M
  • Description
  • Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for th...
More about ETON
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.